Suppr超能文献

血液安全与抗血友病因子浓缩物的选择

Blood safety and the choice of anti-hemophilic factor concentrate.

作者信息

Valentino Leonard A, Oza Veeral M

机构信息

RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics, Rush University Medical Center, Chicago, Illinois 60612, USA.

出版信息

Pediatr Blood Cancer. 2006 Sep;47(3):245-54. doi: 10.1002/pbc.20895.

DOI:10.1002/pbc.20895
PMID:16724312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7168091/
Abstract

Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.

摘要

血友病是一种先天性疾病，由于缺乏凝血因子VIII（经典血友病A）或IX（克里斯马斯病或血友病B）的活性所致。出血很常见，可能导致长期并发症甚至死亡。输注凝血因子浓缩物可治疗或预防出血，然而这些药物并非没有风险。临床医生常常觉得没有充分准备好提供有关这些药物的准确和公正的信息。本综述将为读者提供一个与治疗血友病的浓缩物选择相关的血液安全方面的历史及最新观点。

相似文献

1
Blood safety and the choice of anti-hemophilic factor concentrate.血液安全与抗血友病因子浓缩物的选择
Pediatr Blood Cancer. 2006 Sep;47(3):245-54. doi: 10.1002/pbc.20895.
2
Blood safety and the choice of anti-hemophilic factor concentrate.
Pediatr Blood Cancer. 2007 Jan;48(1):117. doi: 10.1002/pbc.21086.
3
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病：2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.
4
Therapeutic properties and safety of recombinant factor VIII and factor IX.重组凝血因子 VIII 和凝血因子 IX 的治疗特性与安全性。
Pol Arch Med Wewn. 2009 Jun;119(6):403-9.
5
[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].[病毒灭活的凝血因子VIII和IX浓缩物在血友病治疗中的病毒安全性现状]
Infusionsther Transfusionsmed. 1994 Aug;21 Suppl 1:80-3.
6
Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
Med J Aust. 1985 Jul 8;143(1):11-3. doi: 10.5694/j.1326-5377.1985.tb122758.x.
7
[Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].
Folia Haematol Int Mag Klin Morphol Blutforsch. 1990;117(4):595-9.
8
The use of continuous infusion of factor concentrates in the treatment of hemophilia.在血友病治疗中使用凝血因子浓缩物持续输注。
Am J Hematol. 1989 Sep;32(1):8-13. doi: 10.1002/ajh.2830320103.
9
Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate.
Blood. 1979 May;53(5):1012-3.
10
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.血友病患者肌肉骨骼问题的管理。第一部分。血友病的药物治疗原则。
Instr Course Lect. 1983;32:210-6.

引用本文的文献

1
An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review.纳米材料对血浆成分（免疫球蛋白和凝血因子VIII）影响的研究综述：2010 - 2020年回顾
Nanoscale Adv. 2021 May 18;3(13):3730-3745. doi: 10.1039/d1na00119a. eCollection 2021 Jun 30.
2
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.重组凝血因子VIIa在血友病患者出血发作控制中的最佳应用。
Drug Des Devel Ther. 2010 Jul 21;4:127-37. doi: 10.2147/dddt.s6628.
3
Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.哺乳动物细胞表达的重组蛋白治疗药物无血浆制造的新趋势。
Biotechnol J. 2009 Feb;4(2):186-201. doi: 10.1002/biot.200800241.
4
Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A.重组抗血友病因子，无血浆/白蛋白方法（八因子α；ADVATE）用于甲型血友病的治疗。
Vasc Health Risk Manag. 2007;3(5):555-65.

本文引用的文献

1
Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.血友病中新出现病原体的临床意义：变异型克雅氏病的经验
Haemophilia. 2006 Mar;12 Suppl 1:16-20; discussion 26-8. doi: 10.1111/j.1365-2516.2006.01196.x.
2
Emerging viral diseases and infectious disease risks.新出现的病毒性疾病和传染病风险。
Haemophilia. 2006 Mar;12 Suppl 1(Suppl 1):3-7; discussion 26-8. doi: 10.1111/j.1365-2516.2006.01194.x.
3
Clinical perspectives of emerging pathogens in bleeding disorders.出血性疾病中新兴病原体的临床观点。
Lancet. 2006 Jan 21;367(9506):252-61. doi: 10.1016/S0140-6736(06)68036-7.
4
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3.用丙型肝炎病毒NS3蛋白脉冲处理的树突状细胞可诱导免疫反应，并对感染表达NS3的重组痘苗病毒产生保护作用。
J Gen Virol. 2006 Jan;87(Pt 1):1-10. doi: 10.1099/vir.0.81423-0.
5
Advances in chronic viral hepatitis.慢性病毒性肝炎的进展
Curr Opin Infect Dis. 2005 Oct;18(5):400-6. doi: 10.1097/01.qco.0000180163.84271.5e.
6
Transmissible Spongiform Encephalopathies. Managing risk in mammalian organs, cells and sera. 15-16 March 1999, San Diego, CA, USA.传染性海绵状脑病。管理哺乳动物器官、细胞和血清中的风险。1999年3月15 - 16日，美国加利福尼亚州圣地亚哥
IDrugs. 1999 Jun;2(6):564-6.
7
The public health impact of prion diseases.朊病毒疾病对公共卫生的影响。
Annu Rev Public Health. 2005;26:191-212. doi: 10.1146/annurev.publhealth.26.021304.144536.
8
Transfusion-transmitted virus is not present in factor IX concentrates commonly used to treat haemophilia B.常用于治疗乙型血友病的凝血因子IX浓缩物中不存在输血传播病毒。
Haemophilia. 2004 Nov;10(6):732-4. doi: 10.1111/j.1365-2516.2004.01048.x.
9
Successful treatment with cyclosporine and high-dose gamma immunoglobulin for persistent parvovirus B19 infection in a patient with refractory autoimmune hemolytic anemia.环孢素和大剂量γ-免疫球蛋白成功治疗一名难治性自身免疫性溶血性贫血患者的持续性细小病毒B19感染。
Int J Hematol. 2004 Oct;80(3):250-3. doi: 10.1532/ijh97.04017.
10
Inhibitors in congenital coagulation disorders.先天性凝血障碍中的抑制剂。
Br J Haematol. 2004 Nov;127(4):379-91. doi: 10.1111/j.1365-2141.2004.05168.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验